Biomerica, Inc. BMRA
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.33% | 16.82% | -11.80% | -26.04% | -23.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.33% | 16.82% | -11.80% | -26.04% | -23.63% |
| Cost of Revenue | 21.55% | -4.73% | -6.27% | -3.34% | -37.02% |
| Gross Profit | -75.71% | 70.90% | -331.58% | -88.33% | 46.71% |
| SG&A Expenses | -15.49% | 17.70% | 6.32% | 4.94% | -2.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.24% | 4.11% | -1.89% | -1.75% | -21.32% |
| Operating Income | -9.75% | 1.98% | -7.27% | -38.27% | 18.27% |
| Income Before Tax | -24,620.00% | 25.99% | -11.74% | -37.99% | 100.38% |
| Income Tax Expenses | 100.00% | 20.00% | 300.00% | 266.67% | -25.00% |
| Earnings from Continuing Operations | -61,700.00% | 25.84% | -12.81% | -38.95% | 100.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61,700.00% | 25.84% | -12.81% | -38.95% | 100.15% |
| EBIT | -9.75% | 1.98% | -7.27% | -38.27% | 18.27% |
| EBITDA | -10.38% | 1.62% | -7.49% | -39.34% | 18.49% |
| EPS Basic | -46,825.00% | 47.27% | 10.13% | -2.25% | 100.13% |
| Normalized Basic EPS | 10.37% | -18.90% | 10.98% | -1.55% | 33.47% |
| EPS Diluted | -46,825.00% | 46.33% | 9.26% | -2.25% | 100.13% |
| Normalized Diluted EPS | 10.37% | -18.90% | 10.98% | -1.55% | 33.47% |
| Average Basic Shares Outstanding | 24.91% | 40.63% | 25.52% | 35.88% | 25.46% |
| Average Diluted Shares Outstanding | 24.91% | 40.63% | 25.52% | 35.88% | 25.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |